>…isn't [Dr Cox] very, very, very, very, very, very, very, very replaceable (please let me know what he can do that another good manager can't)<
That’s too many very’s!
Put yourself in the position of a prospective buyer who is intrigued by the economics of GTC’s production platform but has little in-house knowledge of how to run an animal pharm. Wouldn’t you want to keep a management team with a proven track record? I know I would.
Dr. Cox may not be the most valuable GTC executive to a prospective buyer—Dr. Meade probably enjoys that distinction—but what Cox knows about taking a transgenics-based drug from preclinical development to regulatory approval is not that readily found, IMO.
Market Data 
Markets 
AI
